RE:waiting for promised JANUARY UPDATES MedMira has successfully developed and validated its VYRATM TriDemic Antigen Rapid Test and has initiated the regulatory approval process for the North American and European market. The Company has secured the clinical site for testing its latest product in Ontario, Canada and shall provide a detailed milestone plan in the month of January with regular updates on its progress.
https://www.medmira.info/post/medmira-introduces-vyra-tridemic